CN109789163A - 用于在治疗肝损伤中使用的基于巨噬细胞的疗法 - Google Patents

用于在治疗肝损伤中使用的基于巨噬细胞的疗法 Download PDF

Info

Publication number
CN109789163A
CN109789163A CN201780056623.2A CN201780056623A CN109789163A CN 109789163 A CN109789163 A CN 109789163A CN 201780056623 A CN201780056623 A CN 201780056623A CN 109789163 A CN109789163 A CN 109789163A
Authority
CN
China
Prior art keywords
macrophage
cell
liver
bmdm
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780056623.2A
Other languages
English (en)
Chinese (zh)
Inventor
斯图尔特·福布斯
菲利普·斯达克·刘易斯
莱斯利·弗雷斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615923.8A external-priority patent/GB201615923D0/en
Priority claimed from GBGB1707183.8A external-priority patent/GB201707183D0/en
Application filed by University of Edinburgh filed Critical University of Edinburgh
Publication of CN109789163A publication Critical patent/CN109789163A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780056623.2A 2016-09-19 2017-09-18 用于在治疗肝损伤中使用的基于巨噬细胞的疗法 Pending CN109789163A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1615923.8 2016-09-19
GBGB1615923.8A GB201615923D0 (en) 2016-09-19 2016-09-19 Macrophage-based therapy
GBGB1707183.8A GB201707183D0 (en) 2017-05-05 2017-05-05 Macrophage-based therapy
GB1707183.8 2017-05-05
PCT/GB2017/052769 WO2018051136A1 (en) 2016-09-19 2017-09-18 Macrophage-based therapy for use in the treatment of liver injury

Publications (1)

Publication Number Publication Date
CN109789163A true CN109789163A (zh) 2019-05-21

Family

ID=60083347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780056623.2A Pending CN109789163A (zh) 2016-09-19 2017-09-18 用于在治疗肝损伤中使用的基于巨噬细胞的疗法

Country Status (6)

Country Link
US (1) US11285174B2 (https=)
EP (2) EP4640237A3 (https=)
JP (1) JP7115755B2 (https=)
CN (1) CN109789163A (https=)
AU (1) AU2017328913B2 (https=)
WO (1) WO2018051136A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884438A (zh) * 2015-10-30 2018-11-23 拜奥拉米那公司 肝细胞的生产方法
CN114622017A (zh) * 2020-12-14 2022-06-14 中山大学孙逸仙纪念医院 Isg15、isg15诱导的巨噬细胞及其分泌物在肿瘤治疗中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2572005A (en) 2018-03-16 2019-09-18 Univ Court Univ Of Edinburgh Macrophage-based therapy
WO2020049552A1 (en) * 2018-09-06 2020-03-12 Technion Research And Development Foundation Limited Tissue repair by activated cells
GB202007905D0 (en) * 2020-05-27 2020-07-08 Univ Edinburgh Cryopressing macrophages
CN111933006B (zh) * 2020-07-30 2022-06-03 四川大学华西医院 一种模拟巨噬细胞改善小鼠急性肾损伤实验的方法及系统
WO2023075623A1 (en) * 2021-10-26 2023-05-04 Ineb (Instituto Nacional De Engenharia Biomédica) Macrophage phenoypes for use in the treatment of intravertebral discs
US20230241250A1 (en) * 2022-02-01 2023-08-03 Massachusetts Institute Of Technology Methods and Compositions to Target and Treat Macrophages
CN115212320B (zh) * 2022-08-04 2025-07-15 温州医科大学慈溪生物医药研究院 一种双靶向脂质体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103977029A (zh) * 2014-04-11 2014-08-13 中国人民解放军第四军医大学 经典激活的巨噬细胞在治疗肝纤维化的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724003B2 (en) * 2015-01-16 2020-07-28 Agency For Science, Technology And Research Method of differentiating human pluripotent stem cells into primitive macrophages

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103977029A (zh) * 2014-04-11 2014-08-13 中国人民解放军第四军医大学 经典激活的巨噬细胞在治疗肝纤维化的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
杨落落: "枯否细胞在对乙酰氨基酚诱导的肝毒性损伤中的作用研究", 《中国博士学位论文全文数据库医药卫生科技辑》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884438A (zh) * 2015-10-30 2018-11-23 拜奥拉米那公司 肝细胞的生产方法
CN108884438B (zh) * 2015-10-30 2022-12-23 拜奥拉米那公司 肝细胞的生产方法
US11713448B2 (en) 2015-10-30 2023-08-01 Biolamina Ab Methods for producing hepatocytes
CN114622017A (zh) * 2020-12-14 2022-06-14 中山大学孙逸仙纪念医院 Isg15、isg15诱导的巨噬细胞及其分泌物在肿瘤治疗中的应用

Also Published As

Publication number Publication date
AU2017328913A1 (en) 2019-02-28
EP4640237A2 (en) 2025-10-29
US11285174B2 (en) 2022-03-29
WO2018051136A9 (en) 2019-02-07
JP7115755B2 (ja) 2022-08-09
JP2019532634A (ja) 2019-11-14
EP4640237A3 (en) 2026-01-07
EP3515460B1 (en) 2025-09-17
WO2018051136A1 (en) 2018-03-22
EP3515460A1 (en) 2019-07-31
AU2017328913B2 (en) 2023-08-17
US20190240256A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
CN109789163A (zh) 用于在治疗肝损伤中使用的基于巨噬细胞的疗法
Cai et al. N2‐polarized neutrophils guide bone mesenchymal stem cell recruitment and initiate bone regeneration: a missing piece of the bone regeneration puzzle
Frodermann et al. Macrophages and cardiovascular health
Gaia et al. Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease
Chen et al. Additional benefit of combined therapy with melatonin and apoptotic adipose‐derived mesenchymal stem cell against sepsis‐induced kidney injury
KR20170116219A (ko) 조직 복구 및 재생을 위한 세포 증식 방법 및 약제학적 제제
Gandhi Pro-and anti-fibrogenic functions of gram-negative bacterial lipopolysaccharide in the liver
Zhao et al. Cloned airway basal progenitor cells to repair fibrotic lung through re-epithelialization
KR102100307B1 (ko) 인간 림프 기관-유래 억제성 기질 세포의 분리 및 용도
Li et al. Therapeutic efficacy and in vivo distribution of human umbilical cord-derived mesenchymal stem cell spheroids transplanted via B-Ultrasound-guided percutaneous portal vein puncture in rhesus monkey models of liver fibrosis
US11622964B2 (en) Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof
WO2014089397A1 (en) Compositions and methods of treating and preventing pulmonary fibrosis
CN107988141A (zh) 肝纤维化模型及其构建方法与应用
Jung et al. Identification of neuronal outgrowth cells from peripheral blood of stroke patients
Danilova et al. Recruitment of macrophages and bone marrow stem cells to regenerating liver promoted by sodium phthalhydrazide in mice
TWI823085B (zh) 嗜中性白血球活化調節劑
Gaowa et al. Recombinant soluble thrombomodulin accelerates epithelial stem cell proliferation in mouse intestinal organoids and promotes the mucosal healing in colitis
WO2018003997A1 (ja) 臓器線維症の予防または治療剤
Ma et al. Endothelial bioreactor system ameliorates multiple organ dysfunction in septic rats
Norman Jr Origin and Maturation of the Pulmonary Lymphatic Endothelium
Davis Examining the immune response to infection in the context of Non-alcoholic fatty liver disease (NAFLD)
CN107970435A (zh) 联合诱导内源Lgr5+肝脏干细胞增多的方法及应用
CN108588010A (zh) 二维培养系统在小鼠肠上皮干细胞体外培养中的应用
Baatjes Eleonore Ngounou
CN107982518A (zh) 一种Lgr5阳性肝脏干细胞诱导方法及其检测应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination